<DOC>
	<DOCNO>NCT01446666</DOCNO>
	<brief_summary>Current practice guideline recommend surveillance hepatocellular carcinoma ( HCC ) liver cirrhosis patient ultrasonography ( USG ) every 6 month . However , advancement cirrhosis , sensitivity USG decrease , risk HCC increase . Gadoxetic acid ( Primovist® ) -enhanced magnetic resonance imaging ( MRI ) demonstrate clinical value diagnosis HCC detection sensitivity 90-95 % , significantly high USG . The hypothesis prove study follow ; Primovist-MRI show significantly high sensitivity compare USG detection early stage HCC imaging modality use interval 6 month patient cirrhosis high risk develop HCC .</brief_summary>
	<brief_title>Gadoxetic Acid-MRI Versus Ultrasonography Surveillance Hepatocellular Carcinoma High-risk Patients</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) currently third lead cause cancer-related death worldwide . Cirrhosis , particularly related viral hepatitis , notable risk factor HCC find nearly 80-90 % case . The stage disease time diagnosis largely determine effectiveness treatment . The treatment advance HCC continue primarily palliative , curative option available early HCC . Unfortunately , less 30 % patient diagnose early enough meet criterion resection , transplantation , local ablation . Surveillance strive detect HCC early stage amenable curative therapy reduce mortality . Current practice guideline recommend surveillance cirrhotic patient ultrasonography ( USG ) every 6 month . However , USG report sensitivity 65 % 80 % use screening test . However , advancement cirrhosis , sensitivity USG decrease , risk HCC increase . Gadoxetic acid ( Primovist® ) -enhanced magnetic resonance imaging ( MRI ) liver demonstrate clinical value local stag HCC surgery assessment patient inconclusive conventional imaging finding . The detection sensitivity Primovist-MRI know high 90-95 % , significantly high USG multiphase computer tomography ( CT ) scan . MRI radiation exposure , meaningful merit use surveillance test . However , MRI never consider surveillance screen HCC . Thus , hypothesis prove study follow ; Primovist-MRI show significantly high sensitivity compare USG detection early stage HCC imaging modality use interval 6 month patient cirrhosis high risk develop HCC . The investigator also analyze whether specificity Primovist-MRI compromise high sensitivity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Patients liver cirrhosis 1 year risk HCC 5 % high meeting follow criterion ; 1 . The evidence cirrhosis etiology within 12 month prior screen Definition cirrhosis follow method 1 ) Histologically liver biopsy ; 2 ) Nonhistologically evidence portal hypertension presence chronic liver disease ; Evidence portal hypertension , include following ; 1 . The identification splenomegaly USG , CT , MRI examinations typical feature cirrhosis 2 . The identification esophageal gastric varix endoscopic examination 2 . High Risk Index ( &gt; =2.33 ) ; Risk Index = 1.65 ( prothrombin activity &lt; =75 % ) + 1.41 ( age 50 year old ) + 0.92 ( platelet count &lt; =100x10 ( 3 ) /mm3 ) + 0.74 ( presence antihepatitis C virus [ HCV ] hepatitis B surface antigen [ HBsAg ] positive ) . 3 . Older 20 year age 4 . Absence previous current history HCC 5 . Absence HCC identify liver USG , dynamic CT , contrastenhanced MRI within 6 month prior screen 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 7 . Patient able comply schedule visit , evaluation plan , study procedure . 8 . Patient willing provide write informed consent Presence follow criterion ; 1 . Active suspected cancer HCC , history malignancy risk recurrence &gt; 20 % within 2 year 2 . ChildPugh score &gt; 9 3 . Significant medical comorbidities survival predict less 3 year 4 . Estimated glomerular filtration rate ( GFR ) &lt; 30 mL/min/1.73m2 5 . Precautions MRI ( cardiac pacemaker , ferromagnetic implant , etc . ) 6 . Severe claustrophobia may interfere protocol compliance . 7 . Any condition , opinion Investigator , would make patient unsuitable enrollment could interfere complete study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>surveillance</keyword>
	<keyword>gadoxetic acid</keyword>
	<keyword>MRI</keyword>
</DOC>